

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Mehraban et al.	Examiner:	YAO, LEI
Serial No.:	09/703,350	Group Art Unit:	1642
Filed:	October 31, 2000	Docket No.:	11669.213USU1
Conf. No.:	3065	Customer No.:	23552
Title:	DIFFERENTIALLY EXPRESSED GENES INVOLVED IN ANGIOGENESIS, THE POLYPEPTIDES THEREBY, AND METHODS OF USING THE SAME		

---

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**(37 C.F.R. § 1.97(b))**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked

as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Date: April 11, 2007

Katharine M. Kowalchyk  
Katharine M. Kowalchyk  
Reg. No. 36,848



<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 11669 213USUI	Application Number: 09/703,350
	Applicant: MEHRABAN ET AL.	
	Filing Date: 10/31/2000	Group Art Unit: 1642

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

  

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

  

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Children's Hospital Boston, Endostatin Update, November 2005
	Lal et al., "Transcriptional Response to Hypoxia in Human Tumors", <u>Journal of the National Cancer Institute</u> , 93(17):1337-1343 (2001)
	McCudden et al., "Co-localization of stanniocalcin-1 ligand and receptor in human breast carcinomas", <u>Molecular and Cellular Endocrinology</u> , 213:167-172 (2004)
	Montesano et al., "Phorbol Esters Induce Angiogenesis in Vitro from Large-Vessel Endothelial Cells", <u>Journal of Cellular Physiology</u> , 130:284-291 (1987)
	Tsopanoglou et al., "Protein Kinase C Involvement in the Regulation of Angiogenesis", <u>J. Vasc. Res.</u> , 30:202-208 (1993)
	Tsopanoglou et al., "Opposing Effects on Modulation of Angiogenesis by Protein Kinase C and cAMP-Mediated Pathways", <u>J. Vasc. Res.</u> , 31:195-204 (1994)
	Wascher et al., "Stanniocalcin-1: A Novel Molecular Blood and Bone Marrow Marker for Human Breast Cancer", <u>Clinical Cancer Research</u> , 9:1427-1435 (2003)

**23552**

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	